TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01917916
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous (s.c.) injection.
Study: NCT01654016
Drug: Detralex
DrugBank: Diosmin (DB08995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detralex 500 mg twice daily for three month prior to surgery
Study: NCT02593643
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02593643
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00216138
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
Study: NCT03933215
Drug: Cladribine Tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study: NCT00109226
Drug: Avastin (Bevacizumab)
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004492
Drug: clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004492
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02009592
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both arms receive Rifaximin
Study: NCT00610246
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
Study: NCT00251511
Drug: Arsenic Trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04007198
Drug: EQ001
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Itolizumab \[Bmab 600\]
Study: NCT01386710
Drug: Bevacizumab and Carboplatin
Normalized name: Carboplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle
Study: NCT01386710
Drug: Bevacizumab and Carboplatin
Normalized name: Carboplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle
Study: NCT04549597
Drug: Tenapanor
Normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of tenapanor
Study: NCT01429792
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard treatment, subcutaneously weekly
Study: NCT01429792
Drug: ribavirin [Copegus]
DrugBank: Ribavirin elaidate (DB17193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment, orally daily
Study: NCT00804258
Drug: intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00102947
Drug: daptomycin (up to 14 days)
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00459043
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given on the first day of every treatment cycle (every 3 weeks)
Study: NCT01184443
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
Study: NCT02499484
Drug: glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical GTN will be used daily in combination with a eccentric home exercise program
Study: NCT02147964
Drug: Acyline
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]
Study: NCT02147964
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
Study: NCT02147964
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketoconazole 400 mg PO daily for 4 months
Study: NCT02147964
Drug: HCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG 60 IU injection Subcutaneously, every other day for 4 months
Study: NCT02147964
Drug: placebo dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo oral dutasteride PO daily for 4 months
Study: NCT02147964
Drug: placebo ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo ketoconazole daily for 4 months
Study: NCT03226223
Drug: Intranasal Methamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
Study: NCT01027208
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lyophilized and solvent, IV, 10-50 mg/m²
Study: NCT03201146
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses to be determined following the completion of Phase I of the study.
Study: NCT03201146
Drug: AP or AC
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
Study: NCT03201146
Drug: Apatinib 250mg
Normalized name: LAPATINIB 250MG TAB
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg/d,q.d.,p.o.every 21 days.
Study: NCT03201146
Drug: Apatinib 500mg
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg/d,q.d.,p.o.every 21 days.
Study: NCT03201146
Drug: Apatinib 750mg
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg/d,q.d.,p.o.every 21 days.
Study: NCT01570686
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily
Study: NCT01794455
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg - 200mg daily
Study: NCT01794455
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg - 32mg daily
Study: NCT00754650
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was supplied as a sterile liquid in single-use vials.
Study: NCT02690987
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of \~130-190 pg/mL.
Study: NCT01823497
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine will be used to control pain post-surgery.
Study: NCT02132234
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: biological treatment according to rheumatologic indication
Study: NCT04050215
Drug: Gallium Ga 68-labeled PSMA-11
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02500043
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
Study: NCT01371747
Drug: patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study: NCT01371747
Drug: patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Study: NCT01371747
Drug: patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study: NCT02132234
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: biological treatment according to rheumatologic indication
Study: NCT01371747
Drug: patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
Study: NCT01371747
Drug: patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Study: NCT02132234
Drug: Certolizumab
Normalized name: certolizumab
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: biological treatment according to rheumatologic indication
Study: NCT02132234
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: biological treatment according to rheumatologic indication
Study: NCT01371747
Drug: patiromer
Normalized name: Patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
Study: NCT01371747
Drug: losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
Study: NCT03507088
Drug: Fluoroestradiol (18F)
Normalized name: fluoroestradiol (18F)
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
Study: NCT00411411
Drug: Januvia
Normalized name: Januvia
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg t.i.d
Study: NCT01415102
Drug: PF-05212372
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled. Dose Level 1: 50 ug
Study: NCT01415102
Drug: PF-05212372
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study: NCT01415102
Drug: PF-05212372
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study: NCT01415102
Drug: PF-05212372
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study: NCT01415102
Drug: PF-05212372
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study: NCT01415102
Drug: PF-05212372
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study: NCT01415102
Drug: PF-05212372
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study: NCT00581165
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recommended dose of enbrel is 25mg administered twice weekly.
Study: NCT00805467
Drug: Fostamatinib Disodium (R935788)
DrugBank: Tamatinib (DB07159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
Study: NCT02965040
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral
Study: NCT00002780
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002780
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03167268
Drug: Lycopene
Normalized name: Lycopene
DrugBank: Lycopene (DB11231)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00318903
Drug: Irinotecan (drug)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
Study: NCT00318903
Drug: Taxotere (drug)
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
Study: NCT01104584
Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
Study: NCT02370498
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT00064467
Drug: Extended-release bupropion (HCl)
Normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03817567
Drug: recombinant anti-EGFR monoclonal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
Study: NCT00948662
Drug: SAM-760
Normalized name: SAM
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
Study: NCT00948662
Drug: ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole oral tablets, 200 mg bid, 14 days
Study: NCT01263691
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline control
Study: NCT03428412
Drug: TCM and conventional drug
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.
Study: NCT00256113
Drug: Saredutant succinate (SR48968C)
Normalized name: succinate
DrugBank: Saredutant (DB06660)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01264094
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clevudine 30 mg qd
Study: NCT00121069
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00696787
Drug: Desvenlafaxine Sustained Release (DVS SR)
Normalized name: desvenlafaxine Extended Release Oral Tablet
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02874404
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02874404
Drug: PI3K-delta Inhibitor TGR-1202
Normalized name: .DELTA.-TOCOPHEROL
DrugBank: Tocopherol (DB11251)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00005050
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01332812
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
Study: NCT00869765
Drug: D-Cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
Study: NCT00702156
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
Study: NCT03598738
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40mg oral tablet, once a day
Study: NCT01911845
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT01772797
Drug: AUY922
Normalized name: AUY922
DrugBank: AUY922 (DB11881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
Study: NCT02765763
Drug: 2-Minute Reveal Masque
Normalized name: TAGETES MINUTA FLOWER OIL
DrugBank: Veal (DB10612)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02765763
Drug: Null Formula 2-Minute Reveal Masque
DrugBank: Veal (DB10612)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00040131
Drug: IL-10
Normalized name: IL-10
DrugBank: Interleukin-10 (DB12880)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03042091
Drug: Polyethylene Glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT03042091
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03042091
Drug: Metronidazole Hydrochloride
Normalized name: metronidazole hydrochloride
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT03059797
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
Study: NCT00593905
Drug: Sitaxsentan
Normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sitaxsentan sodium 100 mg tablet every morning
Study: NCT00593905
Drug: Bosentan, Ambrisentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
Study: NCT00171951
Drug: Pasireotide
Normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide 600 μg or 900 μg was administered as an SC injection.